ClinicalTrials.gg
Not yet recruitingNCT07034131Updated Jul 1, 2025

Evaluation of Osteo-Buddy in Improving Osteoporosis Knowledge

An interventional study of Osteo-Buddy and Usual Care in Osteoporosis Risk and Osteoporosis, Postmenopausal, sponsored by SingHealth Polyclinics. Not yet recruiting. Open to female participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by SingHealth Polyclinics · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Study summary

This is a pilot randomised controlled trial (RCT) to evaluate the use of a Virtual Health Assistant (VHA) named Osteo-Buddy in improving the knowledge of osteoporosis in older women.

Read the detailed description

This study will involve evaluating the preliminary effectiveness and feasibility outcomes of the use of Osteo-Buddy, a Virtual Health Assistant (VHA), in improving the knowledge of osteoporosis in women aged 50 and above.

02

Conditions studied

  • Osteoporosis Risk
  • Osteoporosis, Postmenopausal
03

In context

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

This study's planned enrollment of 80 is below the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.

Browse Osteoporosis, Postmenopausal studies →

Lead sponsor

SingHealth Polyclinics is the lead sponsor of 23 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50 and above
  • Medium or high Osteoporosis Self-Assessment Tool for Asians (OSTA) score
  • Not undertaken Bone Mineral Density (BMD) scan
  • Never been treated with anti-osteoporosis medications such as bisphosphonates (e.g. alendronate, risendronate, ibandronate, zolendronate, pamidronate) or denosumab
  • Able to read and speak English
  • Currently use and own a smartphone where Osteo-Buddy can be used

Exclusion criteria

Exclusion Criteria:

  • Known terminal illness
  • Visual, hearing and/or cognitive impairment or mental illness that renders them unable to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Intervention

    use of Osteo-Buddy for 4 weeks

    Other: Osteo-Buddy · Other: Usual Care

  • Experimental
    Control

    usual care - access to digitalised educational materials titled 'Healthy Bones'

    Other: Usual Care

Interventions

  • OtherOsteo-Buddy

    Osteo-Buddy is a Virtual Health Assistant (VHA) accessible on mobile phones that helps users with: 1. Evaluating their risk level of osteoporosis 2. Recommending screening and referrals 3. Lifestyle interventions through motivation, education and tailored guidance As a 24/7 VHA, it offers real-time, personalised advice based on user inputs and health data.

  • OtherUsual Care

    Access to digitalised educational materials on osteoporosis, titled 'Healthy Bones'

06

What researchers measure

Primary outcomes

  1. Osteoporosis Prevention and Awareness Tool (OPAAT) score

    * 30-item questionnaire measuring osteoporosis knowledge * Minimum value = 0, maximum value = 30 * Higher scores indicate a better outcome

    Time frame: On enrolment and 6-8 weeks post enrolment

  2. System Usability Scale (SUS)

    * 10-item questionnaire assessing usability * Minimum value = 0, maximum value = 100 * Higher scores mean a better outcome

    Time frame: 6-8 weeks post enrolment

Secondary outcomes

  1. Recruitment rate

    Percentage of participants successfully recruited among referred participants

    Time frame: over the course of recruitment, estimated 3-4 months

  2. Retention rate

    Percentage of recruited participants who complete the study (return for 2nd visit and successfully complete 2nd questionnaire)

    Time frame: 6-8 weeks post-enrolment

  3. Utility rate

    Percentage of intervention arm participants who utilise Osteo-Buddy over the 4 weeks

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — In view of concerns regarding patient confidentaility and data security, IPD will not be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Mar 2026, 8 months later.

Of 48 non-industry interventional studies with no phase under Osteoporosis, Postmenopausal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's planned 8 months is below that.

Counting every sponsor, half of 51 studies reached it within 17 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2025
First posted
Jun 24, 2025
StartEst.
Jul 2025
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07034131
Lead sponsor
SingHealth Polyclinics
Responsible party
Eunice Lim Shi Min (Family Physician, SingHealth Polyclinics) — Principal investigator
First posted
Jun 24, 2025
Start date
Jul 2025 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Jul 1, 2025

Study contacts

Eunice Lim
Contact
eunice.lim.s.m@singhealth.com.sg
+65 6340 7436
Eunice Lim
principal investigator · SingHealth Polyclinics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion